Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat

Abstract

Aim: Multiple myeloma (MM) is a hematological malignancy of antibody-producing mature B cells or plasma cells. The proteasome inhibitor, bortezomib, was the first-in-class compound to be FDA approved for MM and is frequently utilized in induction therapy. However, bortezomib refractory disease is a major clinical concern, and the efficacy of the pan-histone deacetylase inhibitor (HDACi), panobinostat, in bortezomib refractory disease indicates that HDAC targeting is a viable strategy. Here, we utilized isogenic bortezomib resistant models to profile HDAC expression and define baseline and HDACi-induced expression patterns of individual HDAC family members in sensitive vs. resistant cells to better understanding the potential for targeting these enzymes.

Methods: Gene expression of HDAC family members in two sets of isogenic bortezomib sensitive or resistant myeloma cell lines was examined. These cell lines were subsequently treated with HDAC inhibitors: panobinostat or vorinostat, and HDAC expression was evaluated. CRISPR/Cas9 knockdown and pharmacological inhibition of specific HDAC family members were conducted.

Results: Interestingly, HDAC6 and HDAC7 were significantly upregulated and downregulated, respectively, in bortezomib-resistant cells. Panobinostat was effective at inducing cell death in these lines and modulated HDAC expression in cell lines and patient samples. Knockdown of HDAC7 inhibited cell growth while pharmacologically inhibiting HDAC6 augmented cell death by panobinostat.

Conclusion: Our data revealed heterogeneous expression of individual HDACs in bortezomib sensitive vs. resistant isogenic cell lines and patient samples treated with panobinostat. Cumulatively our findings highlight distinct roles for HDAC6 and HDAC7 in regulating cell death in the context of bortezomib resistance.

Keywords

Histone deacetylase / bortezomib resistance / selective HDAC inhibitors / HDAC6 / HDAC7

References

[1] Kyle RA.Multiple myeloma.Blood2008;111:2962-72 PMCID:PMC2265446

[2] Scott K,Will A,Coyne I.Bortezomib for the treatment of multiple myeloma.Cochrane Database Syst Rev2016;4:CD010816

[3] Brower V.Bortezomib improves survival in rare myeloma.Lancet Oncol2016;17:e227

[4] Richardson PG,Mitsiades C.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.J Clin Oncol2009;27:3518-25 PMCID:PMC2717758

[5] Manasanch EE.Proteasome inhibitors in cancer therapy.Nat Rev Clin Oncol2017;14:417-33 PMCID:PMC5828026

[6] Orlowski RZ.Why proteasome inhibitors cannot ERADicate multiple myeloma.Cancer Cell2013;24:275-7 PMCID:PMC3863636

[7] Tandon N,Kumar SK.Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.Clin Pharmacol2016;8:35-44 PMCID:PMC4866749

[8] Laubach JP,San-Miguel JF.Panobinostat for the treatment of multiple myeloma.Clin Cancer Res2015;21:4767-73

[9] Popat R,Flanagan L.Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.Lancet Haematol2016;3:e572-80

[10] Ocio EM,Atadja P.In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.Haematologica2010;95:794-803 PMCID:PMC2864386

[11] Richardson PG,Alsina M.PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.Blood2013;122:2331-7

[12] Li Y.HDACs and HDAC inhibitors in cancer development and therapy.Cold Spring Harb Perspect Med2016;6:a026831 PMCID:PMC5046688

[13] Stahl M,Vey N.Lost in translation?.Expert Opin Investig Drugs2016;25:307-17

[14] Jones PA,Baylin S.Targeting the cancer epigenome for therapy.Nat Rev Genet2016;17:630-41

[15] Boyault C,Pabion M.HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.Oncogene2007;26:5468-76

[16] Li Y,Kwon SH.Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.FEBS J2013;280:775-93

[17] Kim GW,Won HR.A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.Leuk Res2020;95:106398

[18] Parra M.Class IIa HDACs - new insights into their functions in physiology and pathology.FEBS J2015;282:1736-44

[19] Barneda-Zahonero B,Azagra A.The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.Cell Death Dis2015;6:e1635 PMCID:PMC4669785

[20] Bakin RE.Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis.J Biol Chem2004;279:51218-25

[21] Ma C.Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism.J Biol Chem2011;286:4819-28 PMCID:PMC3039335

[22] García-Guerrero E,Doose S.Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.Leukemia2021;35:201-14 PMCID:PMC8318885

[23] Ramkumar P,Tian R.CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.Blood Adv2020;4:2899-911 PMCID:PMC7362346

[24] Tzogani K,Walsh I.EMA review of panobinostat (Farydak) for the treatment of adult patients with relapsed and/or refractory multiple myeloma.Oncologist2018;23:631-6 PMCID:PMC5947444

[25] Brioli A,Hochhaus A.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Expert Rev Hematol2017;10:193-205

[26] Laubach JP,Mariz M.Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.Lancet Oncol2021;22:142-54

[27] Atadja P.Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.Cancer Lett2009;280:233-41

[28] Kikuchi J,Shimizu R.Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.Blood2010;116:406-17

[29] Kuhn DJ,Jones RJ.Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.Blood2012;120:3260-70 PMCID:PMC3476538

[30] Kuhn DJ,Voorhees PM.Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.Blood2007;110:3281-90 PMCID:PMC2200918

[31] Jin Z,Dechow PC.HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered β-catenin switch.Mol Endocrinol2013;27:325-35 PMCID:PMC3683803

[32] Bradley EW,Olson EN.Histone deacetylase 7 (Hdac7) suppresses chondrocyte proliferation and β-catenin activity during endochondral ossification.J Biol Chem2015;290:118-26 PMCID:PMC4281714

[33] Margariti A,Xiao Q.Histone deacetylase 7 controls endothelial cell growth through modulation of beta-catenin.Circ Res2010;106:1202-11

[34] Azagra A,Collazo O.In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development.J Exp Med2016;213:2591-601 PMCID:PMC5110011

[35] Rao R,Yang Y.HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.Blood2008;112:1886-93

[36] North BJ,Tamang D,Jones SS.Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.PLoS One2017;12:e0173507 PMCID:PMC5338861

[37] Hideshima T,Paranal RM.Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.Proc Natl Acad Sci U S A2016;113:13162-7 PMCID:PMC5135369

[38] Vogl DT,Jagannath S.Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma.Clin Cancer Res2017;23:3307-15 PMCID:PMC5496796